Positive News SentimentPositive NewsNASDAQ:ABVC ABVC BioPharma (ABVC) Stock Price, News & Analysis $2.92 -0.08 (-2.67%) Closing price 04:00 PM EasternExtended Trading$2.92 0.00 (0.00%) As of 06:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About ABVC BioPharma Stock (NASDAQ:ABVC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ABVC BioPharma alerts:Sign Up Key Stats Today's Range$2.89▼$3.0250-Day Range$2.65▼$3.3052-Week Range$0.40▼$5.48Volume20,753 shsAverage Volume391,189 shsMarket Capitalization$68.74 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview ABVC BioPharma is a clinical-stage biotechnology company focused on the discovery and development of novel vaccine and immunotherapy candidates for oncology and infectious diseases. The company leverages a proprietary peptide-based platform to identify and synthesize immunogenic epitopes, aiming to stimulate targeted immune responses against tumor-associated and pathogen-derived antigens. The company’s pipeline includes active immunotherapy programs designed to address a range of cancer indications, along with vaccine candidates targeting bacterial pathogens. ABVC BioPharma applies its platform to generate both personalized and off-the-shelf candidates, with preclinical and early-stage clinical studies evaluating safety, immunogenicity and preliminary efficacy. Headquartered in Research Triangle Park, North Carolina, ABVC BioPharma operates research laboratories in North America and collaborates with academic and industry partners to advance its development programs. The company’s leadership team is composed of executives and scientists with experience in peptide chemistry, immunology and clinical development, guiding its efforts to bring new vaccine-based therapies to market.AI Generated. May Contain Errors. Read More ABVC BioPharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks17th Percentile Overall ScoreABVC MarketRank™: ABVC BioPharma scored higher than 17% of companies evaluated by MarketBeat, and ranked 861st out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for ABVC BioPharma.Read more about ABVC BioPharma's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of ABVC BioPharma is -17.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ABVC BioPharma is -17.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioABVC BioPharma has a P/B Ratio of 48.33. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about ABVC BioPharma's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.43% of the float of ABVC BioPharma has been sold short.Short Interest Ratio / Days to CoverABVC BioPharma has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ABVC BioPharma has recently decreased by 2.35%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldABVC BioPharma does not currently pay a dividend.Dividend GrowthABVC BioPharma does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.43% of the float of ABVC BioPharma has been sold short.Short Interest Ratio / Days to CoverABVC BioPharma has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ABVC BioPharma has recently decreased by 2.35%, indicating that investor sentiment is improving. News and Social Media3.2 / 5News SentimentN/A News SentimentABVC BioPharma has a news sentiment score of 1.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for ABVC BioPharma this week, compared to 1 article on an average week.MarketBeat Follows2 people have added ABVC BioPharma to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, ABVC BioPharma insiders have not sold or bought any company stock.Percentage Held by Insiders17.10% of the stock of ABVC BioPharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 11.38% of the stock of ABVC BioPharma is held by institutions.Read more about ABVC BioPharma's insider trading history. Receive ABVC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ABVC BioPharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ABVC Stock News HeadlinesABVC BioPharma Highlighted by U.S. Financial Media as One of the Best Biotech Investments; Q3 Licensing Revenue Reaches $1.27 Million, With Clear Clinical Progress Across CNS ...October 17, 2025 | finance.yahoo.comABVC BioPharma, Inc. (ABVC) Reports 103% Asset Surge, Eyeing Phase III Trials for Depression TherapiesSeptember 24, 2025 | msn.comNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $25 trillion AI revolution — one that Nvidia’s CEO himself has called a “multi-trillion-dollar future industry” — and he’s uncovered a little-known stock 168 times smaller than Nvidia that could be positioned to ride this breakthrough.October 21 at 2:00 AM | Brownstone Research (Ad)ABVC BioPharma Reports US$1.03 Million in Total Licensing Revenues Collected in Q3 to Date, Highlighting High-Margin Business ModelSeptember 19, 2025 | finance.yahoo.comABVC BioPharma Receives $450,000 in Licensing Payments From OncoX BioPharma in Q3 2025August 29, 2025 | finance.yahoo.comBioLite, Inc., an ABVC BioPharma Subsidiary, Receives $230,000 Milestone Payment from AiBtl, Advancing Botanical Drug Licensing CollaborationAugust 27, 2025 | finance.yahoo.comABVC BioPharma Receives $100,000 Milestone Payment From ForSeeCon, Strengthening Vitargus(R) Licensing DealAugust 22, 2025 | finance.yahoo.comABVC BioPharma First Half 2025 Earnings: US$0.19 loss per share (vs US$0.36 loss in 1H 2024)August 15, 2025 | finance.yahoo.comSee More Headlines ABVC Stock Analysis - Frequently Asked Questions How have ABVC shares performed this year? ABVC BioPharma's stock was trading at $0.59 on January 1st, 2025. Since then, ABVC shares have increased by 391.5% and is now trading at $2.90. How were ABVC BioPharma's earnings last quarter? ABVC BioPharma, Inc. (NASDAQ:ABVC) announced its quarterly earnings data on Wednesday, August, 13th. The company reported ($0.13) earnings per share (EPS) for the quarter. When did ABVC BioPharma's stock split? Shares of ABVC BioPharma reverse split on Tuesday, July 25th 2023.The 1-10 reverse split was announced on Tuesday, July 25th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, July 25th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did ABVC BioPharma IPO? ABVC BioPharma (ABVC) raised $7 million in an initial public offering (IPO) on Tuesday, August 3rd 2021. The company issued 1,100,000 shares at a price of $6.25 per share. How do I buy shares of ABVC BioPharma? Shares of ABVC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ABVC BioPharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that ABVC BioPharma investors own include Meta Platforms (META), NIO (NIO), ObsEva (OBSV), Tesla (TSLA), Alibaba Group (BABA), ChargePoint (CHPT) and Walt Disney (DIS). Company Calendar Last Earnings8/13/2025Today10/21/2025Next Earnings (Estimated)11/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ABVC CIK1173313 Webwww.abvcpharma.com Phone(510)-668-0881FaxN/AEmployees30Year Founded2002Profitability EPS (Trailing Twelve Months)($0.17) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$4.90 million Net MarginsN/A Pretax Margin-1,160.36% Return on Equity-46.76% Return on Assets-23.02% Debt Debt-to-Equity RatioN/A Current Ratio0.42 Quick Ratio0.42 Sales & Book Value Annual Sales$510 thousand Price / Sales134.78 Cash FlowN/A Price / Cash FlowN/A Book Value$0.06 per share Price / Book48.67Miscellaneous Outstanding Shares23,540,000Free Float19,516,000Market Cap$68.74 million OptionableNot Optionable Beta0.30 Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:ABVC) was last updated on 10/21/2025 by MarketBeat.com Staff From Our PartnersTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | Sponsored7 market signals flashing red right nowRight now, the same 7 key indicators that predicted 1929, the 1970s stagflation, and the 2008 meltdown are all...American Alternative | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ABVC BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ABVC BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
